Recombinant Human SLAM/CD150 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11480-SL

SLAMF1
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11480-SL-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

Q13291.1

Conjugate

Unconjugated

Applications

Bioactivity

View all SLAM/CD150 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human SLAM/CD150 protein
Human SLAM
(Ala21-Lys236)
Accession # Q13291.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala21,Tyr23,Thr25

Predicted Molecular Mass

51 kDa

SDS-PAGE

60-80 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
Recombinant Human SLAM/CD150 Fc Chimera binds to Biotinylated SLAM/CD150 protein with an ED50 of 0.100-1.00 μg/mL.

Scientific Data Images for Recombinant Human SLAM/CD150 Fc Chimera Protein, CF

Recombinant Human SLAM/CD150 Fc Chimera Protein Binding Activity.

Recombinant Human SLAM/CD150 Fc Chimera Protein (Catalog # 11480-SL) binds to Biotinylated SLAM/CD150 protein with an ED50 of 0.100-1.00 μg/mL.

Recombinant Human SLAM/CD150 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human SLAM/CD150 Fc Chimera Protein (Catalog # 11480-SL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-80 kDa and 120-160 kDa, respectively.

Formulation, Preparation and Storage

11480-SL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: SLAM/CD150

Signaling lymphocytic activation molecule (SLAM), also known as SLAMF1 and CD150, is the founding member of the SLAM subfamily of the CD2 protein family (1, 2). SLAM is a single-pass type I membrane glycoprotein that functions as an adhesion molecule and plays an active role in the regulation of innate and adaptive immunity (1, 2, 4). Mature SLAM consists of an extracellular domain (ECD) containing an Ig-like V-type domain and an Ig-like C2-type domain, a helical transmembrane domain, and a cytoplasmic tail containing 2 immunoreceptor tyrosine-based switch motifs (ITSM) (3, 4). The ECD of human SLAM shares human SLAM shares 58% and 56% amino acid sequence identity with mouse and rat SLAM, respectively.. In human, several isoforms resulting from alternative splicing have been identified with functional diversity (4). SLAM is expressed on T cells, B cells, thymocytes, macrophages, dendritic cells, platelets, and hematopoietic stem cells, and it is up-regulated on activated B cells and CD4+ and CD8+ T cells (4 – 6). SLAM interacts homophilically with low affinity, and this interaction induces a Th0/Th1 phenotype in CD8+ T cells that is characterized by clonal expansion, production of IFN-gamma, and increased cytolytic activity (7, 8). SLAM also plays a role in activation of the PI3K-Akt signaling pathway through its association with the adapter molecule SAP (9). In humans, SLAM functions as a cellular entry receptor for measles virus (10, 11). SLAM deregulation is associated with genomic complexity and independently predicts a worse outcome in chronic lymphocytic leukemia (CLL) (12). 

References

  1. Yurchenko, M. et al. (2018) J. Cell. Biol. 217:1411.
  2. Pellegrini, J. et al. (2021) Autophagy. 17:2629.
  3. Wang, N. et al. (2015) Front. Immunol. 6:158.
  4. Gordiienko, I. (2019) Clinical Immunol. 204:14.
  5. Calpe, S. et al. (2008) Adv Immunol. 97:177. 
  6. Wang, N. et al. (2004) J. Exp. Med. 199:1255.
  7. Mavaddat, N. et al. (2000) J. Biol. Chem. 275:28100. 
  8. Mehrle, S. et al. (2008) Mol. Immunol. 45:796. 
  9. Yurchenko, M.Y. et al. (2005) Exp Oncol. 27:24.
  10. Hsu, E.C. et al. (2001) Virology 279:9.
  11. Gonçalves-Carneiro, D. et al. (2017) J Virol. 91:e02255.
  12. Gian, M.R. et al. (2021) Br. J. Haematol. 192:1068.

Long Name

Signaling Lymphocytic Activation Molecule

Alternate Names

CD150, IPO-3, SLAMF1

Entrez Gene IDs

6504 (Human); 27218 (Mouse); 102135470 (Cynomolgus Monkey)

Gene Symbol

SLAMF1

UniProt

Q13291.1

Additional SLAM/CD150 Products

Product Documents for Recombinant Human SLAM/CD150 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human SLAM/CD150 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.